This research explores biopharmaceutical companies' organizational readiness for transformational partnerships and more specifically, for the prevention of CMDs (phenomenon of interest). The researcher posited a relationship between organizational, leadership, and readiness factors and organizational readiness to engage in transformational partnerships within biopharmaceutical companies. A sequential, qualitative research design was utilized to maximize the assessment of the current state of organizational readiness for subunits of prevention and partnership in context. Results from a document analysis and semi-structured interviews, the researcher concluded that there are challenges for BC organizational-level readiness for effective and impactful achievement of SDG 3 via transformational partnerships that will have a significant impact on population health; however, a great deal of thought, effort, and motivation is present. These insights highlight the practice- and leadership-oriented elements that support more transformational, systems-level change.
","abstract_html":"<p dir="ltr">This research explores biopharmaceutical companies' organizational readiness for transformational partnerships and more specifically, for the prevention of CMDs (phenomenon of interest). The researcher posited a relationship between organizational, leadership, and readiness factors and organizational readiness to engage in transformational partnerships within biopharmaceutical companies. A sequential, qualitative research design was utilized to maximize the assessment of the current state of organizational readiness for subunits of prevention and partnership in context. Results from a document analysis and semi-structured interviews, the researcher concluded that there are challenges for BC organizational-level readiness for effective and impactful achievement of SDG 3 via transformational partnerships that will have a significant impact on population health; however, a great deal of thought, effort, and motivation is present. These insights highlight the practice- and leadership-oriented elements that support more transformational, systems-level change.</p>","abstract_has_math":false,"creators":["Kelly Olsson (22799519)"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026-02-17T00:00:00Z","date_published":"2026-02-17T00:00:00Z","updated_at":"2026-07-27T21:34:08Z","subjects":["Organizational readiness for change","Adaptive Leadership","Pharmaceutical and health care","Primary Prevention of the Disease","cardiometabolic disease prevented","Transformational - transactional leadership","Partnerships in healthcare","cross sector collaboration","Public health partnerships"],"languages":[],"rights":["In Copyright"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://doi.org/10.25417/uic.31341331.v1","outbound_label":"DOI","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Kelly Olsson (22799519)"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2026-02-17T00:00:00Z"]},{"key":"dc:relation","label":"Dc Relation","values":["https://figshare.com/articles/thesis/Organizational_Readiness_for_Transformational_Partnerships_in_Biopharmaceutical_Companies/31341331"]},{"key":"dc:type","label":"Dc Type","values":["Text","Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Organizational readiness for change","Adaptive Leadership","Pharmaceutical and health care","Primary Prevention of the Disease","cardiometabolic disease prevented","Transformational - transactional leadership","Partnerships in healthcare","cross sector collaboration","Public health partnerships"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:rights","label":"Dc Rights","values":["In Copyright"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["10.25417/uic.31341331.v1"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["This research explores biopharmaceutical companies' organizational readiness for transformational partnerships and more specifically, for the prevention of CMDs (phenomenon of interest). The researcher posited a relationship between organizational, leadership, and readiness factors and organizational readiness to engage in transformational partnerships within biopharmaceutical companies. A sequential, qualitative research design was utilized to maximize the assessment of the current state of organizational readiness for subunits of prevention and partnership in context. Results from a document analysis and semi-structured interviews, the researcher concluded that there are challenges for BC organizational-level readiness for effective and impactful achievement of SDG 3 via transformational partnerships that will have a significant impact on population health; however, a great deal of thought, effort, and motivation is present. These insights highlight the practice- and leadership-oriented elements that support more transformational, systems-level change.
"]},{"key":"dc:title","label":"Title","values":["Organizational Readiness for Transformational Partnerships in Biopharmaceutical Companies"]}]}],"canonical_facts":{"dc:creator":["Kelly Olsson (22799519)"],"dc:date":["2026-02-17T00:00:00Z"],"dc:description":["This research explores biopharmaceutical companies' organizational readiness for transformational partnerships and more specifically, for the prevention of CMDs (phenomenon of interest). The researcher posited a relationship between organizational, leadership, and readiness factors and organizational readiness to engage in transformational partnerships within biopharmaceutical companies. A sequential, qualitative research design was utilized to maximize the assessment of the current state of organizational readiness for subunits of prevention and partnership in context. Results from a document analysis and semi-structured interviews, the researcher concluded that there are challenges for BC organizational-level readiness for effective and impactful achievement of SDG 3 via transformational partnerships that will have a significant impact on population health; however, a great deal of thought, effort, and motivation is present. These insights highlight the practice- and leadership-oriented elements that support more transformational, systems-level change.
"],"dc:identifier":["10.25417/uic.31341331.v1"],"dc:relation":["https://figshare.com/articles/thesis/Organizational_Readiness_for_Transformational_Partnerships_in_Biopharmaceutical_Companies/31341331"],"dc:rights":["In Copyright"],"dc:subject":["Organizational readiness for change","Adaptive Leadership","Pharmaceutical and health care","Primary Prevention of the Disease","cardiometabolic disease prevented","Transformational - transactional leadership","Partnerships in healthcare","cross sector collaboration","Public health partnerships"],"dc:title":["Organizational Readiness for Transformational Partnerships in Biopharmaceutical Companies"],"dc:type":["Text","Thesis"]},"updated_at":"2026-07-27T21:34:08Z"}